[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Moderna Inc (MRNA)

Moderna Inc (MRNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Moderna's Revenue Decline May Be Slowing, But Analyst Uncertainty Lingers Around Execution

Moderna Inc (MRNA) reports second-quarter 2026 earnings before the market opens on Friday, July 31st, with analysts expecting a loss of $1.97 per share. The biotech company has consistently beaten estimates over the past four quarters, but investors will be watching closely to see if the company can maintain momentum as it navigates the post-pandemic landscape and advances its pipeline beyond COVID-19 vaccines. With the stock trading at $57.92 and options pricing a 6.49% expected move, this report could provide critical insight into whether Moderna's diversification strategy is gaining traction.

Moderna Inc is a biotechnology company that develops messenger RNA (mRNA) medicines, with a...

Fundamentals

See More
  • Market Capitalization, $K 21,620,870
  • Shares Outstanding, K 396,786
  • Annual Sales, $ 1,944 M
  • Annual Income, $ -2,822 M
  • EBIT $ -3,412 M
  • EBITDA $ -3,264 M
  • 60-Month Beta 0.94
  • Price/Sales 11.39
  • Price/Cash Flow N/A
  • Price/Book 2.99

Options Overview Details

View History
  • Implied Volatility 87.17% (-9.01%)
  • Historical Volatility 84.33%
  • IV Percentile 85%
  • IV Rank 67.21%
  • IV High 103.33% on 11/03/25
  • IV Low 54.03% on 08/06/25
  • Expected Move (DTE 1) 3.76 (6.49%)
  • Put/Call Vol Ratio 1.10
  • Today's Volume 29,210
  • Volume Avg (30-Day) 42,376
  • Put/Call OI Ratio 1.18
  • Today's Open Interest 576,925
  • Open Int (30-Day) 585,095
  • Expected Range 54.16 to 61.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.97
  • Number of Estimates 8
  • High Estimate $-1.32
  • Low Estimate $-2.35
  • Prior Year $-2.13
  • Growth Rate Est. (year over year) +7.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.35 +8.58%
on 07/28/26
85.60 -32.34%
on 07/06/26
-12.11 (-17.29%)
since 06/30/26
3-Month
43.68 +32.60%
on 05/01/26
85.60 -32.34%
on 07/06/26
+11.98 (+26.08%)
since 04/30/26
52-Week
22.28 +159.96%
on 11/21/25
85.60 -32.34%
on 07/06/26
+25.77 (+80.16%)
since 07/30/25

Most Recent Stories

More News
Moderna's Revenue Decline May Be Slowing, But Analyst Uncertainty Lingers Around Execution

Barchart Research What to Expect from MRNA Earnings MRNA Generated July 30, 2026 Current Price $57.92 EPS Estimate $$-1.97 Consensus Rating Hold Average Move 6.13% Moderna's Revenue Decline May Be Slowing,...

MRNA : 57.92 (+6.29%)
Moderna (MRNA) Q2 Earnings: What To Expect

Moderna (MRNA) Q2 Earnings: What To Expect

MRNA : 57.92 (+6.29%)
1 Healthcare Stock to Keep an Eye On and 2 We Avoid

1 Healthcare Stock to Keep an Eye On and 2 We Avoid

TXG : 49.43 (+6.71%)
CAH : 227.07 (-0.89%)
MRNA : 57.92 (+6.29%)
Option Volatility And Earnings Report For July 27-31

It is a mammoth week on the earnings front with a plethora of important companies reporting. This week could make or break the market. This week we have Apple, Microsoft, Amazon, Meta Platforms, Exxon...

MSTR : 97.74 (+4.73%)
META : 539.03 (-7.95%)
AAPL : 333.43 (-1.41%)
BE : 207.12 (+26.49%)
MU : 874.66 (+18.36%)
COIN : 163.58 (+2.18%)
MSFT : 451.10 (+15.51%)
TSLA : 308.85 (+3.53%)
SBUX : 105.85 (+1.64%)
XOM : 156.97 (+0.14%)
MRNA : 57.92 (+6.29%)
HOOD : 86.60 (-3.61%)
Q1 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks

Q1 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks

MRNA : 57.92 (+6.29%)
Therapeutics Stocks Q1 Highlights: Moderna (NASDAQ:MRNA)

Therapeutics Stocks Q1 Highlights: Moderna (NASDAQ:MRNA)

MRNA : 57.92 (+6.29%)
Earnings Preview: What To Expect From Moderna’s Report

Moderna is likely to announce its fiscal second-quarter earnings by the end of this month, and analysts expect its losses to narrow.

XLV : 163.52 (-1.64%)
$SPX : 7,437.63 (+1.66%)
MRNA : 57.92 (+6.29%)
14 S&P 500 Stocks Are Up Over 100% in 2026. Why Micron Is My Favorite for the Rest of the Year.

Among the 14 S&P 500 stocks that have surged more than 100% so far this year, Micron stands out as my top pick.

AMAT : 501.77 (+14.97%)
GOOG : 333.68 (-0.62%)
GOOGL : 333.66 (-0.91%)
META : 539.03 (-7.95%)
SNDK : 1,279.96 (+25.99%)
$SPX : 7,437.63 (+1.66%)
MU : 874.66 (+18.36%)
LITE : 693.24 (+15.09%)
DVA : 238.86 (-0.87%)
MSFT : 451.10 (+15.51%)
FTNT : 154.25 (+0.67%)
STX : 851.68 (+11.41%)
Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings?

Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings?

MRNA : 57.92 (+6.29%)
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors

CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer...

MRNA : 57.92 (+6.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency...

See More

Key Turning Points

3rd Resistance Point 62.72
2nd Resistance Point 60.40
1st Resistance Point 59.16
Last Price 57.92
1st Support Level 55.60
2nd Support Level 53.28
3rd Support Level 52.04

See More

52-Week High 85.60
Fibonacci 61.8% 61.41
Last Price 57.92
Fibonacci 50% 53.94
Fibonacci 38.2% 46.47
52-Week Low 22.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.